Mepolizumab para el tratamiento de asma grave eosinofílica
Comisión Nacional de Evaluación de Tecnologías de Salud (CONETEC) (CONETEC).
s.l; CONETEC; jun. 2022.
Não convencional Espanhol | BRISA | ID: biblio-1379662
Documentos relacionados
[Perfilamiento del paciente con asma grave eosinofílica para el tratamiento biológico con Mepolizumab y su efectividad en el control de la enfermedad].
Anti-IL-5 therapies for asthma.
Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison.
Super-responders to anti-IL-5/anti-IL-5R are characterised by high sputum eosinophil counts at baseline.
Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma.
Comparative Efficacy of Anti IL-4, IL-5 and IL-13 Drugs for Treatment of Eosinophilic Asthma: A Network Meta-analysis.
Targeting the interleukin-5 pathway improves cough hypersensitivity in patients with severe uncontrolled asthma.
Evaluación económica y análisis de impacto presupuestario de mepolizumab en asma eosinofílica refractaria grave
A Phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma.
Interleukin-5 Antagonists Usher in a New Generation of Asthma Therapy.